Insight Lifetech是一家中国医疗设备公司,于2026年2月5日在上海STAR市场上揭幕,每股17.52元,在50.31元开业。 Insight Lifetech, a Chinese medical device firm, debuted on Shanghai’s STAR Market on Feb. 5, 2026, raising CNY17.52 per share and opening at CNY50.31.

Insight Lifetech是一家中国医疗设备公司,成立于2015年,于2026年2月5日在上海证券交易所的STAR市场上揭幕,每股筹集17.52元,在50.31时开放,市场上限为209.8亿元。 Insight Lifetech, a Chinese medical device company founded in 2015, debuted on the Shanghai Stock Exchange’s STAR Market on February 5, 2026, raising CNY17.52 per share and opening at CNY50.31 with a market cap of CNY20.98 billion. 该公司是唯一一家国内公司,拥有内部超声波和分流储备系统中的核准产品,包括中国第一个国内核准的FFR装置和由NMPA和CE MDR清理的60MHz高清晰IVUS系统。 It is the only domestic firm with approved products in both intravascular ultrasound and fractional flow reserve systems, including China’s first domestically approved FFR device and a 60MHz high-definition IVUS system cleared by both NMPA and CE MDR. 该公司在市场上有11种产品,还有几种产品正在开发,用于心血管治疗和静脉纤维发炎治疗。 The company has 11 products on the market and several in development for cardiovascular and atrial fibrillation treatments. Qiming Venture Partners, 一家主要投资者,在IPO之前持有超过6%的股份。 Qiming Venture Partners, a major investor, held over 6% of shares before the IPO. 该公司旨在减少对进口设备的依赖,并通过创新和临床质量扩大全球影响。 The company aims to reduce reliance on imported devices and expand global impact through innovation and clinical quality.